Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note released on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, Maxim Group raised shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 target price […]
5 Oct 03:54 · The Cerbat Gem